Get Counsel Health Terms in Writing Before Oura's $625M Buy

If your health plan or health system embeds Counsel Studio, your AI primary care vendor is about to become a subsidiary of a wearable maker that sells to your members. You probably have until the end of this year to get its new owner's commitments on paper. Oura announced on November 10 that it will buy Counsel Health for $625 million in cash, subject to purchase price adjustments. Counsel says it will keep serving existing and new enterprise partners. Nothing published so far says what happens to partner data, partner roadmap requests or partner exit rights once Oura owns the platform.

The continuity promise is the right starting point and a thin one. A health plan's leverage is highest before the deal closes, while the buyer still wants partners to stay calm, and Counsel's own release puts that close before the end of the calendar year. (TechCrunch reported the close as expected before the end of 2027; the company's text is the one to plan against, and it gives you about seven weeks.)

What Oura Is Buying for $625 Million

Oura is buying a physician-backed AI care service, and Counsel Studio, the version other companies put inside their own apps. Counsel pairs a chat-based medical AI with licensed physicians who step in when the AI should not answer alone. Its CEO, Muthu Alagappan, will join Oura as chief clinical AI officer, and Counsel's roughly 70 employees will move over, according to Bloomberg as cited by TechCrunch.

The two companies already work together. Counsel went live inside the Oura app in June, where members can start with Counsel's medical AI "for clinical questions informed by their Oura data" and move to a board-certified physician in the same conversation. So Oura has watched the product work at its own scale before paying for it.

The price is large against what Counsel raised. The startup took a $25 million Series A led by a16z and GV about a year ago, and PitchBook puts its total funding at $36 million. Oura can afford it: preliminary, unaudited figures in the release show quarterly revenue of $533 million, up 153% year over year, with $87 million in adjusted EBITDA. The deal comes weeks after Oura postponed an IPO that could have raised up to $2.2 billion, citing market uncertainty.

---

What Counsel Studio Does Inside Your App

Counsel Studio is a white-label AI primary-care layer: your app, your logo and your clinical protocols, with Counsel's AI and physicians underneath. It launched in July as a platform that lets health plans, health systems and consumer health apps add physician-supervised AI primary care to their existing digital front doors, connected by iFrame, WebView or API.

The Counsel Studio product page lists what a partner hands over and gets back: ingestion of "proprietary data sources", care pathways aligned to the partner's clinical protocols, labs, prescriptions and specialist referrals, and full UI customization down to "Your app, logo, colors and type." It promises go-live "in weeks, not years." It publishes no enterprise price.

The performance numbers are Counsel's own. At launch the company said its infrastructure serves more than 8 million people, resolves 96% of issues without escalation and saves $381 a year per engaged member. The product page adds a 40%+ reduction in urgent care use and a two-minute average physician response time. No health plan or health system partner is named on either page, so none of these figures comes with a customer you can call. Treat them as a vendor's claims until your own claims data agrees.

That design is what makes the ownership change matter. A plan that embeds Studio sends member records and its own protocols into Counsel, and Counsel's AI acts on them under the plan's brand. The member does not see Counsel. After closing, they will not see Oura either.

Why a Wearable Owner Changes Your Contract Risk

Oura's interests overlap with yours more than a typical software acquirer's would, because it sells a consumer product to the same population your member app serves. Three questions follow from that, and the public material answers none of them.

The first is data. Counsel's current privacy policy, last modified June 23, 2024, lets it disclose information "in connection with a merger, divestiture, restructuring" and to "subsidiaries and affiliates." It also says "We and our LLM partners may use your data for the purpose of generating responses to your chats." That policy governs Counsel's consumer users. Your members' data should be governed by your business associate agreement, and the question is whether that agreement, as written, stops a post-close Counsel from using de-identified partner data to improve products Oura sells to its own members. Oura's CEO Tom Hale said in 2025, during a backlash over its defense work, that "We will never sell your data to anyone ever". Selling is the narrow case; model training and product analytics inside one corporate family are the ones to pin down.

The second is roadmap priority. Oura and Counsel say they plan to expand their partnership across preventive, acute, specialty and chronic care. Counsel has about 70 people. When an Oura feature and a health plan's integration request compete for the same engineers, the parent company's product is the likely winner, and your contract is the only thing that says otherwise.

The third is channel conflict. In September Counsel joined the CMS Innovation Center's ACCESS Model on its early cardio-kidney-metabolic track, starting in early 2027, with Oura as "technology and marketing partner" that promotes Counsel's Medicare chronic-care program to Oura members. ACCESS is a 10-year CMS model that ties payment to measurable clinical improvement. A plan or health system that runs its own chronic-care programs now licenses its care layer from a company that also enrolls patients directly under Medicare and has a consumer brand to recruit them.

The strongest case for staying calm deserves a hearing. A startup with $36 million in funding was a continuity risk on its own; an owner with Oura's revenue makes a shutdown less likely, and Counsel's stated goal is to reach patients beyond Oura's member base, which needs enterprise partners. All of that can be true and still leave the three questions above to your contract.

---

What Happened the Last Time a Consumer Giant Bought a Care Provider

Regulators have already shown where they look in this kind of deal: the buyer's use of health data it did not collect itself. When Amazon closed its $3.9 billion purchase of One Medical in February 2023, the FTC let it close but said it was still weighing harms from Amazon controlling and using "sensitive consumer health information held by One Medical."

Oura's deal is a sixth of that size and may draw less scrutiny. Counsel's release mentions no regulatory approvals. That puts more of the work on partners: if no regulator asks how member data moves between Counsel and Oura, the BAA is where the answer gets written down.

HIPAA gives you a floor to stand on. A business associate contract must require the vendor, at termination, to "return or destroy all protected health information" it holds for you where feasible, and must let you terminate if the vendor violates a material term. Neither clause gives you the right to leave because the vendor changed owners. That right comes from a change-of-control clause, if you negotiated one.

We have covered the same pattern in other healthcare AI deals: Ellipsis Health's purchase of Kouper put EHR scheduling into a voice-agent vendor, Sopris's purchase of Blackford Analysis raised the same business associate question for radiology AI customers, and Agilent's Proscia deal put a hardware maker in charge of a pathology platform its rivals' customers depend on.

---

What to Get in Writing Before the Deal Closes

The goal is to convert "Counsel will continue serving enterprise partners" into dated, contractual commitments while Oura still has a reason to give them.

This Week:

1. Pull your Counsel Studio order form, master agreement and BAA, and have counsel mark three clauses: change of control, assignment, and termination for convenience. If none lets you exit on a change of owner, you are negotiating from goodwill.
2. Ask your Counsel account lead, in writing, whether the existing BAA will remain with the Counsel entity after closing or be assigned to Oura, and whether Oura will countersign it.
3. List every data feed you send Studio (eligibility, claims, EHR extracts, protocols) so you know exactly what a data-use restriction has to cover.

This Month:

1. Request a side letter, signed before closing, stating that your members' PHI and any data derived from it, including de-identified data, will not be used to train or improve Oura consumer products or shared with Oura outside the services you contracted for.
2. Ask for a named service-level and support commitment through your current term, plus notice of at least 12 months before any Studio feature you use is retired.
3. If you run chronic-care programs, ask how Counsel will separate your members from its own ACCESS enrollment and from Oura's marketing to the same people.

Before Renewal:

1. Write a change-of-control termination right into the renewal, with data return or destruction within a fixed number of days and a certificate of destruction.
2. Ask for the partner references Counsel has not published, and test the 96% resolution and $381 savings claims against your own utilization data before you price the renewal.
3. Keep one alternative embedded-care vendor in a live evaluation so the renewal is a real decision. Our note on keeping PHI out of Gemini for Healthcare until a BAA is confirmed covers the questions to ask any new entrant.

The Bottom Line

Oura wants clinical care because a ring produces data and a care service can turn that data into treatment and revenue. For a health plan, the useful part of this deal is the timing. Counsel's own release says it closes before the end of the year, and the commitments you need on member data, roadmap and exit cost far less to get before that date than after it. Five9's Level AI deal and OpenAI's Odessia purchase show the two ends of what a buyer can decide for acquired customers.

Send the BAA question to your Counsel account lead this week.

Continue Reading

• Keep PHI Out of Gemini for Healthcare Until Google Confirms BAA
• Ellipsis Health Buys Kouper to Let Sage Book EHR Visits
• Sopris Buys Blackford Analysis From Bayer to Merge Into Azra AI
• Agilent's $240M Proscia Buy Puts Scanner Choice in Agilent's Hands
• Five9 to Acquire Level AI for $325M, Keep Selling to Rivals
• OpenAI Acquires Odessia as Its AI Travel Service Closes